Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_assertion type Assertion NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_head.
- NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_assertion description "[RRM1 has been studied in a large number of patients with different types of cancer, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, and biliary tract cancer, to establish its prognostic or predictive value when patients were treated with gemcitabine, and mRNA expression and genetic variants as determined by genotyping have in some cases been associated with clinical outcome of patients with cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_provenance.
- NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_assertion evidence source_evidence_literature NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_provenance.
- NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_assertion SIO_000772 21163702 NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_provenance.
- NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_assertion wasDerivedFrom befree-20150227 NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_provenance.
- NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_assertion wasGeneratedBy ECO_0000203 NP676499.RAQ9mx3Hbbf-BjU3RwBuTZq12tTo6ytV-jjZSFsJFchFU130_provenance.